Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sihuan Pharmaceutical Holdings (SHPHF) Fair Value & Analysis

Healthcare · US · Market cap $1.9B

Price$0.1297
Fair Value$0.0500
Upside-61.4%
Quality82/100
Evidence: Medium Range $0.0500 – $0.0700

Fair value as of: Jun 24, 2026

Analysis

Sihuan Pharmaceutical Holdings (SHPHF) currently trades at $0.1297, while our model-based Fair Value estimate is $0.0500 — implying the stock looks roughly 61.4% overvalued today. We read business quality at 82/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China, the United States, and internationally. It operates in three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic devices, body sculpturing, skin care, and other services, as well as non- or minimally invasive comprehensive medical aesthetics solutions. It also provides drugs for cardio-cerebral vascular, digestive system, anti-infective, metabolism, respiratory, neurology, oncology, diabetes, and other indications, as well as modern Chinese medicine and industrial hemp products. In addition, the company offers general hospital services. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is Sihuan Pharmaceutical Holdings (SHPHF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.0500 versus a price of $0.1297 — about −61% (overvalued). Model-based estimate, not financial advice.
What is the fair value of SHPHF?
Our 21-model fair value for Sihuan Pharmaceutical Holdings is $0.0500 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.1297.
What is the quality score of SHPHF?
Sihuan Pharmaceutical Holdings has a Quality Score of 82/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.